Evaluation of intra-arterial infusion chemotherapy for advanced gastric cancer
Kosaka, T.; Ueshige, N.; Sugaya, J.; Nakano, Y.; Akiyama, T.; Tomita, F.; Saito, H.; Kita, I.; Takashima, S.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 25(9): 1288-1291
1998
ISSN/ISBN: 0385-0684 PMID: 9703810 Document Number: 496326
We evaluated the therapeutic efficacy of intraarterial infusion chemotherapy in advanced gastric cancer, its side effect and patient prognosis, in comparison with systemic infusion. Of 125 cases of advanced gastric cancer, 41 cases received intraarterial chemotherapy (A group) and the rest were given systemic infusion (S group). Protocols of chemotherapy were 5-FU + MTX in 49 cases, 5-FU + cisplatin in 62, and 5-FU + MMC in 14. Location of the disease was the peritoneum in 69 cases, nodes in 59, liver in 38, and other sites, 33. The response rate of A group was significantly higher than that of S group, at 31% and 13% respectively. Although 41% of cases showed side effects (> or = grade 2), there was no significant difference between the 2 groups. The median survival period and 1-year survival rate were 8.4 months and 35%, respectively, and there was no significant difference between the 2 groups. In cases with liver metastasis, the prognosis of A group was better than that of S group. The results suggest that intra-arterial infusion chemotherapy is an effective treatment for liver metastasis from gastric cancer.